Your browser doesn't support javascript.
loading
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Baden, Lindsey R; Stieh, Daniel J; Sarnecki, Michal; Walsh, Stephen R; Tomaras, Georgia D; Kublin, James G; McElrath, M Juliana; Alter, Galit; Ferrari, Guido; Montefiori, David; Mann, Philipp; Nijs, Steven; Callewaert, Katleen; Goepfert, Paul; Edupuganti, Srilatha; Karita, Etienne; Langedijk, Johannes P; Wegmann, Frank; Corey, Lawrence; Pau, Maria G; Barouch, Dan H; Schuitemaker, Hanneke; Tomaka, Frank.
Afiliação
  • Baden LR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: lbaden@bwh.harvard.edu.
  • Stieh DJ; Janssen Vaccines & Prevention, Leiden, Netherlands.
  • Sarnecki M; Janssen Vaccines, Bern, Switzerland.
  • Walsh SR; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Tomaras GD; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Ferrari G; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Montefiori D; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Mann P; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Nijs S; Janssen Infectious Diseases, Beerse, Belgium.
  • Callewaert K; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Goepfert P; Division of Infectious Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Edupuganti S; Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Karita E; Rwanda Zambia HIV Research Group, Kigali, Rwanda.
  • Langedijk JP; Janssen Vaccines & Prevention, Leiden, Netherlands.
  • Wegmann F; Janssen Vaccines & Prevention, Leiden, Netherlands.
  • Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Pau MG; Janssen Vaccines & Prevention, Leiden, Netherlands.
  • Barouch DH; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Schuitemaker H; Janssen Vaccines & Prevention, Leiden, Netherlands.
  • Tomaka F; Janssen Research and Development, Titusville, NJ, USA.
Lancet HIV ; 7(10): e688-e698, 2020 10.
Article em En | MEDLINE | ID: mdl-33010242
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2020 Tipo de documento: Article País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2020 Tipo de documento: Article País de publicação: Holanda